Method for treating autoimmune diseases
Patent 7067139 Issued on June 27, 2006. Estimated Expiration Date: 
May 21, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 21, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesSteroid formulation Anti-arthritic preparation Method for stimulating red blood cell production Method for treating canine distemper Composition containing peptides and nucleic acids and methods of making same Treatment of basal cell carcinoma with product R, a peptide-nucleic acid preparation Patent #: 5902786 InventorAssigneeApplicationNo. 09316624 filed on 05/21/1999US Classes:424/278.1, NONSPECIFIC IMMUNOEFFECTOR, PER SE (E.G., ADJUVANT, NONSPECIFIC IMMUNOSTI- MULATOR, NONSPECIFIC IMMUNOPOTENTIATOR, NONSPECIFIC IMMUNOSUPPRESSOR, NON- SPECIFIC IMMUNOMODULATOR, ETC.); OR NONSPECIFIC IMMUNOEFFECTOR, STABILIZER, EMULSIFIER, PRESERVATIVE, CARRIER, OR OTHER ADDITIVE FOR A COMPOSITION CON- TAINING AN IMMUNOGLOBULIN, AN ANTISERUM, AN ANTIBODY, OR FRAGMENT THEREOF, AN ANTIGEN, AN EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR424/535, Milk or colostrum (e.g., butter, whey, etc.)424/548, Derived from musculoskeletal system, other than cardiac muscle (e.g., cartilage, muscle, etc.)424/529, Blood514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/21, Produced by or extracted from animal tissue514/44, Polynucleotide (e.g., RNA, DNA, etc.)536/23.1, DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)514/161, With heterocyclic compound210/651Removing specified materialExaminersPrimary: Zeman, Mary K.Assistant: Clow, Lori A. Attorney, Agent or FirmInternational ClassesA61K 45/00A61K 38/00 A61K 31/70 AbstractA method of treating patients having rheumatoid arthritis by administering Product R, a peptide-nucleic acid preparation, is disclosed.Other References
Field of SearchNONSPECIFIC IMMUNOEFFECTOR, PER SE (E.G., ADJUVANT, NONSPECIFIC IMMUNOSTI- MULATOR, NONSPECIFIC IMMUNOPOTENTIATOR, NONSPECIFIC IMMUNOSUPPRESSOR, NON- SPECIFIC IMMUNOMODULATOR, ETC.); OR NONSPECIFIC IMMUNOEFFECTOR, STABILIZER, EMULSIFIER, PRESERVATIVE, CARRIER, OR OTHER ADDITIVE FOR A COMPOSITION CON- TAINING AN IMMUNOGLOBULIN, AN ANTISERUM, AN ANTIBODY, OR FRAGMENT THEREOF, AN ANTIGEN, AN EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTORINVOLVING AUTOIMMUNITY, ALLERGY, IMMEDIATE HYPERSENSITIVITY, DELAYED HYPERSENSITIVITY, IMMUNOSUPPRESSION, IMMUNOTOLERANCE, OR ANERGY Blood Milk or colostrum (e.g., butter, whey, etc.) Derived from musculoskeletal system, other than cardiac muscle (e.g., cartilage, muscle, etc.) Conjugate or complex includes hormone or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or fragment thereof Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI Produced by or extracted from animal tissue Glycoprotein (carbohydrate containing) Polynucleotide (e.g., RNA, DNA, etc.) Purines (including hydrogenated) (e.g., adenine, guanine, etc.) Pyrimidines (including hydrogenated) (e.g., cytosine, etc.) ARTHRITIS IMMUNE RESPONSE AFFECTING DRUG DNA or RNA fragments or modified forms thereof (e.g., genes, etc.) PEPTIDES OF 3 TO 100 AMINO ACID RESIDUES |
| ||||||||||||||
